ChiCTR2200057788 版本V1.5 版本创建时间2022/11/21 19:29:52 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200057788 

最近更新日期:

Date of Last Refreshed on:

2022-11-21 19:27:41 

注册时间:

Date of Registration:

2022-03-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请联系我们上传伦理审批文件。 隔药灸脐疗法干预肾阳虚型薄型子宫内膜患者FET结局的随机对照研究及机制探讨

Public title:

A randomized controlled study and mechanism of intervention on FET outcome in patients with thin endometrium with kidney-Yang deficiency

注册题目简写:

English Acronym:

研究课题的正式科学名称:

隔药灸脐疗法干预肾阳虚型薄型子宫内膜患者FET结局的随机对照研究及机制探讨

Scientific title:

A randomized controlled study and mechanism of intervention on FET outcome in patients with thin endometrium with kidney-Yang deficiency

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2200005737

申请注册联系人:

夏庆昌 

研究负责人:

马玉侠 

Applicant:

Xia Qingchang 

Study leader:

Ma Yuxia 

申请注册联系人电话:

Applicant telephone:

+86 18364167369

研究负责人电话:

Study leader's
telephone:

+86 18364167369

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

doctoraric@163.com

研究负责人电子邮件:

Study leader's E-mail:

PHDmayuxia@126.COM

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市历下区经十路16369号

研究负责人通讯地址:

山东省济南市历下区经十路16369号

Applicant address:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

Study leader's address:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

申请注册联系人邮政编码:

Applicant postcode:

250014

研究负责人邮政编码:

Study leader's postcode:

250014

申请人所在单位:

山东中医药大学

Applicant's institution:

Shandong University of Traditional Chinese Medicin

研究负责人所在单位:

山东中医药大学

Affiliation of the Leader:

Shandong University of Traditional Chinese Medicin

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SDUTCM-E2021051403

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

山东中医药大学附属医院中西医结合生殖与遗传中心伦理委员会

Name of the ethic committee:

Ethics Committee of Reproduction and Genetics Center of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Shandong University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

宋景艳

Contact Name of the ethic committee:

Song Jingyan

伦理委员会联系地址:

山东省济南市历下区经十路16369号

Contact Address of the ethic committee:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 18364167369

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东中医药大学

Primary sponsor:

Shandong Traditional Chinese Medicine University

研究实施负责(组长)单位地址:

山东省济南市历下区经十路16369号

Primary sponsor's address:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学

具体地址:

历下区经十路16369号

Institution
hospital:

Shandong Traditional Chinese Medicine University

Address:

16369 Jingshi Road, Lixia District

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

薄型子宫内膜  

Target disease:

Thin endometrium

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

观察隔药灸脐疗法对肾阳虚型薄型子宫内膜患者冻胚移植(Frozen embryo transfer, FET)的临床结局影响。  

Objectives of Study:

To observe the clinical outcome of the Frozen embryo transfer (FET) in patients with kidney-yang deficiency thin endometrium by moxibustion umbilical therapy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合不孕症、薄型子宫内膜的诊断标准及中医肾阳虚辨证标准;
2.20 ≤年龄≤42周岁;
3.受试前3个月未使用过任何甾体激素类药物;
4.拮抗剂促排卵方案取卵,现余优质冷冻胚胎1~2枚;
5.签署知情同意书。

Inclusion criteria

1. Meet the diagnostic criteria of infertility and thin endometrium and the syndrome differentiation criteria of kidney Yang deficiency in traditional Chinese medicine;
2. Aged 20 -42 years;
3. The subjects had not used any steroid hormone drugs in the previous 3 months;
4. There were 1-2 high-quality frozen embryos left in the antagonist ovulation-stimulating scheme;
5. Sign the informed consent form.

排除标准:

1.哺乳期及妊娠期女性;
2.患有多囊卵巢综合征、子宫内膜异位症、高催乳素血症、子宫肌瘤等妇科疾病;
3.既往卵巢肿瘤病史或卵巢手术史;
4.合并有心脑血管疾病、肝肾功严重异常及造血系统等有严重疾病的患者,精神病患者;
5.既往放、化疗史;
6.对脐疗药粉过敏者;
7.脐周有病变,不宜艾灸者;
8.正在参加其他临床试验者;
9.不能按规定接受隔药灸脐治疗,无法判断疗效或资料不全等影响疗效及安全性判断者。

Exclusion criteria:

1. Lactating and pregnant patients;
2. Patients with polycystic ovary syndrome, endometriosis, hyperprolactitinemia, uterine fibroids and other gynecological diseases;
3. Previous history of ovarian tumor or ovarian surgery;
4. Patients with cardiovascular and cerebrovascular diseases, severe abnormalities of liver and kidney function, hematopoietic system and other serious diseases, mental patients;
5. Previous history of radiotherapy and chemotherapy;
6. Patients who are allergic to umbilical therapy powder;
7. There are lesions around the umbilicus, which should not be moxibustion;
8. Participating in other clinical trials;
9. Patients who cannot receive moxibustion umbilical cord treatment with drug isolation according to regulations, cannot judge the efficacy or have incomplete data that affect the efficacy and safety judgment.

研究实施时间:

Study execute time:

From 2022-03-15 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-03-15 00:00:00 To 2023-03-15 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

隔药灸脐+激素替代方案

干预措施代码:

Intervention:

Moxibustion umbilicus + hormone replacement program

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

替代方案

干预措施代码:

Intervention:

Hormone replacement program

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学附属医院 

单位级别:

三甲 

Institution
hospital:

Affiliated Hospital of Shandong University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子宫内膜厚度

指标类型:

主要指标

Outcome:

Endometrial thickness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 42 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由申请人使用SPASS 22进行随机分配

Randomization Procedure (please state who generates the random number sequence and by what method):

Random allocation by applicants using SPASS 22

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

山东中医药大学

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Shandong Traditional Chinese Medicine University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-03-17 20:22:42